Metabolic Therapy for Neurodegenerative Diseases

📖 Wiki Page

therapeutic1126 wordssynced 2026-04-02

Metabolic Therapy for Neurodegenerative Diseases

Introduction

...

Metabolic Therapy for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Metabolic Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Ketone</td>
<td>Brain Transport</td>
</tr>
<tr>
<td class="label">β-Hydroxybutyrate</td>
<td>MCT1 transporter</td>
</tr>
<tr>
<td class="label">Acetoacetate</td>
<td>Passive diffusion</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Protocol</td>
</tr>
<tr>
<td class="label">Calorie Restriction</td>
<td>20-30% caloric reduction</td>
</tr>
<tr>
<td class="label">Intermittent Fasting</td>
<td>16:8 or 5:2 protocols</td>
</tr>
<tr>
<td class="label">Time-Restricted Eating</td>
<td>Daily eating window</td>
</tr>
<tr>
<td class="label">Fasting-Mimicking Diet</td>
<td>5-day monthly cycle</td>
</tr>
<tr>
<td class="label">Source</td>
<td>Coconut oil, palm kernel oil</td>
</tr>
<tr>
<td class="label">Key Molecules</td>
<td>C8 (caprylic acid), C10 (capric acid)</td>
</tr>
<tr>
<td class="label">Brain Entry</td>
<td>Direct via MCT1 transporter</td>
</tr>
<tr>
<td class="label">Conversion</td>
<td>Liver to ketone bodies</td>
</tr>
<tr>
<td class="label">Role</td>
<td>Gluconeogenesis substrate</td>
</tr>
<tr>
<td class="label">CNS Entry</td>
<td>Monocarboxylate transporters</td>
</tr>
<tr>
<td class="label">Energy</td>
<td>Glycolysis intermediate</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Pyruvate dehydrogenase kinase</td>
</tr>
<tr>
<td class="label">Effect</td>
<td>Activates PDH complex</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Phase 2 trials</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT02561468</td>
<td>Ketogenic diet</td>
</tr>
<tr>
<td class="label">NCT03472664</td>
<td>MCT oil</td>
</tr>
<tr>
<td class="label">NCT05338411</td>
<td>Fasting-mimicking diet</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT03962712</td>
<td>Ketogenic diet</td>
</tr>
<tr>
<td class="label">NCT03795727</td>
<td>DCA</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Use</td>
</tr>
<tr>
<td class="label">Fasting glucose</td>
<td>Metabolic status</td>
</tr>
<tr>
<td class="label">HbA1c</td>
<td>Long-term glucose</td>
</tr>
<tr>
<td class="label">Insulin</td>
<td>Insulin sensitivity</td>
</tr>
<tr>
<td class="label">Ketone bodies</td>
<td>Ketosis</td>
</tr>
<tr>
<td class="label">Lactate</td>
<td>Glycolysis</td>
</tr>
<tr>
<td class="label">FDG-PET</td>
<td>Cerebral glucose</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Ketogenic + Exercise</td>
<td>Synergistic mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Fasting + Exercise</td>
<td>Autophagy activation</td>
</tr>
<tr>
<td class="label">MCT + Exercise</td>
<td>Enhanced ketone uptake</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Ketogenic + Acetylcholinesterase inhibitors</td>
<td>Multiple mechanisms</td>
</tr>
<tr>
<td class="label">Fasting + Metformin</td>
<td>Autophagy + metabolic</td>
</tr>
<tr>
<td class="label">DCA + CoQ10</td>
<td>Mitochondrial support</td>
</tr>
</table>

Metabolic Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Mermaid diagram (expand to render)

Metabolic therapy encompasses interventions that target energy metabolism dysfunction in neurodegenerative diseases. Brain hypometabolism is a hallmark of neurodegeneration, with impaired glucose utilization, mitochondrial dysfunction, and reduced ATP production contributing to neuronal death [@cunnane2011]. [@mosconi2008]

Pathogenic Role of Metabolic Dysfunction

Brain Hypometabolism in AD

Reduced glucose uptake in posterior cingulate and [hippocampus](/brain-regions/hippocampus)
Impaired insulin signaling (Type 3 diabetes hypothesis)
Decreased mitochondrial function
Reduced pyruvate dehydrogenase activity [@mosconi2008]

Metabolic Dysfunction in PD

Complex I deficiency in substantia nigra
Impaired glucose metabolism
Altered lactate dynamics
ATP depletion in dopaminergic [neurons](/entities/neurons) [@schapira2014]

Energy Crisis in ALS

Mitochondrial dysfunction in motor neurons
Impaired glucose metabolism
Reduced ATP production
Energy deficit contributing to excitotoxicity

Therapeutic Approaches

Ketogenic Diet

The ketogenic diet shifts brain metabolism from glucose to ketone bodies (β-hydroxybutyrate, acetoacetate), providing an alternative fuel source. [@schapira2014]

Mechanisms:

Increased mitochondrial biogenesis
Reduced oxidative stress
Enhanced GABAergic inhibition
Improved insulin sensitivity
Activation of protective signaling pathways [@paoli2019]

Clinical Evidence in AD:

Improved cognition in mild cognitive impairment
Reduced [Aβ](/proteins/amyloid-beta) in CSF
Increased cerebral ketone uptake
Ongoing Phase 3 trials

Clinical Evidence in PD:

Motor symptom improvement in small trials
Reduced OFF time
Potential disease-modifying effects

Calorie Restriction and Intermittent Fasting

Mechanisms:

Autophagy induction ([mTOR](/entities/mtor) inhibition)
Reduced inflammation
Improved insulin sensitivity
Enhanced BDNF expression
Mitochondrial quality control [@mattson2014]

Metabolic Agents

Medium-Chain Triglycerides (MCTs)

Clinical Evidence:

Improved cognition in AD (MCT oil supplementation)
Dose-dependent ketone production
Well-tolerated with GI side effects

Pyruvate

Clinical Evidence:

Improved cerebral metabolism in AD
Combined with exercise shows synergy

Dichloroacetate (DCA)

Clinical Evidence:

Reduced lactate in PD
Improved motor function
Ongoing studies in ALS

Disease-Specific Applications

Alzheimer's Disease

Metabolic Targets:

Cerebral glucose hypometabolism
Insulin resistance
Mitochondrial dysfunction

Clinical Trials:

Outcomes:

Improved cognitive scores
Reduced amyloid on PET
Increased cerebral blood flow

Parkinson's Disease

Metabolic Targets:

Complex I deficiency
Glucose hypometabolism
Lactate accumulation

Clinical Trials:

Outcomes:

Reduced OFF time
Improved UPDRS scores
Better motor fluctuations

Amyotrophic Lateral Sclerosis

Metabolic Targets:

Energy deficit
Mitochondrial dysfunction
Hypermetabolism

Clinical Trials:

High-calorie diets being explored
Metabolic enhancers in development
Combination with riluzole

Huntington's Disease

Metabolic Targets:

Energy deficit in striatum
Mitochondrial dysfunction
Weight loss/metabolism

Clinical Evidence:

Ketogenic diet may improve motor function
High-calorie diets prevent weight loss
Metabolic agents in development

Biomarkers for Monitoring

Combination Strategies

Metabolic Therapy + Exercise

Metabolic Therapy + Pharmacologic

Adverse Effects and Contraindications

Ketogenic Diet

Common Side Effects:

Constipation
Nutrient deficiencies
Elevated cholesterol
Kidney stones (rare)

Contraindications:

Pancreatic insufficiency
Liver failure
Carnitine deficiency
Pregnancy

Fasting

Risks:

Hypoglycemia
Dehydration
Muscle loss
Electrolyte imbalance

Contraindications:

Diabetes (type 1)
Eating disorders
Malnutrition
Pregnancy

Future Directions

Personalized Metabolic Therapy

Genetic testing for metabolic risk factors
Biomarker-guided protocols
Individualized diet composition

Novel Agents

Exogenous ketone supplements
Metabolic gene therapy
Mitochondrial transfer therapy
NAD+ precursors

Technology-Enabled Monitoring

Continuous glucose monitors
Ketone sensors
Wearable metabolic tracking

External Links

[ClinicalTrials.gov - Ketogenic Diet Neurodegeneration](https://clinicaltrials.gov/search?cond=neurodegenerative&intr=ketogenic)
[ fasting-mimicking diet research](https://www.lchfresearch.org/)
[Mitochondrial Medicine Society](https://www.mitosoc.org/)

Background

The study of Metabolic Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Cunnane SC, et al, Brain fuel metabolism, aging, and Alzheimer's disease (2011)

Mosconi L, et al, Brain glucose hypometabolism and cognitive impairment in AD (2008)

Schapira AH, Mitochondrial dysfunction in Parkinson's disease (2014)

Paoli A, et al, Beyond weight loss: the potential of ketogenic diet for neurodegenerative diseases (2019)

Mattson MP, et al, Fasting: molecular mechanisms and clinical applications (2014)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupling](/hypothesis/h-seaad-v4-29e81bbc) — 0.56 · Target: SLC16A1
[Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits](/hypothesis/h-827a821b) — 0.53 · Target: PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes
[The Glial Ketone Metabolic Shunt Hypothesis](/hypothesis/h-4b517512) — 0.51 · Target: HMGCS2
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Metabolic Therapy for Neurodegenerative Diseases

Metabolic Therapy for Neurodegenerative Diseases

Introduction

Metabolic Therapy for Neurodegenerative Diseases

Introduction

Overview

Pathogenic Role of Metabolic Dysfunction

Brain Hypometabolism in AD

Metabolic Dysfunction in PD

Energy Crisis in ALS

Therapeutic Approaches

Ketogenic Diet

Calorie Restriction and Intermittent Fasting

Metabolic Agents

Medium-Chain Triglycerides (MCTs)

Pyruvate

Dichloroacetate (DCA)

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Biomarkers for Monitoring

Combination Strategies

Metabolic Therapy + Exercise

Metabolic Therapy + Pharmacologic

Adverse Effects and Contraindications

Ketogenic Diet

Fasting

Future Directions

Personalized Metabolic Therapy

Novel Agents

Technology-Enabled Monitoring

See Also

External Links

Background

References

Related Hypotheses